Page 1

Table of Contents ( Mark One ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , DC 20549 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10 - K Biohaven Pharmaceutical Holding Company Ltd. ( Exact Name of Registrant as Specified in its Charter ) British Virgin Islands ( State or other jurisdiction of incorporation or organization ) c / o Biohaven Pharmaceuticals , Inc. 215 Church Street , New Haven , Connecticut ( Address of principal executive offices ) Commission File Number : 001-38080 Securities registered pursuant to Section 12 ( b ) of the Act : Title of each class Common Shares , without par value ( 203 ) 404-0410 ( Registrant's telephone number , including area code ) N / A ( Former address ) Large accelerated filer Non - accelerated filer Trading Symbol BHVN Not applicable ( I.R.S. Employer Identification No. ) 06510 ( Zip Code ) Name of each exchange on which registered New York Stock Exchange Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes ý No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Exchange Act . Yes o No ý Indicate by check mark whether the registrant : ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes ý No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes ý No o Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or emerging growth company . See the definitions of " large accelerated filer , " " accelerated filer , " " smaller reporting company , " and " emerging growth company " in Rule 12b - 2 of the Exchange Act . Accelerated filer Small reporting company Emerging growth company 0 0 0 If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . o Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . < Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . Yes No ý The aggregate market value of the registrant's common shares held by non - affiliates of the registrant as of the last business day of the registrant's most recently completed second fiscal quarter , June 30 , 2020 , based on the last reported sale price of the registrant's common stock on the New York Stock Exchange on June 30 , 2020 of $ 73.11 , was $ 3.265 billion . The calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose . As of February 25 , 2021 , there were 61,915,440 common shares , no par value per share , outstanding . Documents Incorporated by Reference Portions of the registrant's definitive Proxy Statement to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934 for its 2021 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10 - K .